The earnings call highlighted a strong start to 2025 with significant achievements in EPS growth, business momentum in Kabi and Helios, and strategic deleveraging. However, challenges such as the absence of energy relief in Germany, potential U.S. tariff impacts, and market challenges in China were noted.

Company Guidance -

Q3 2025

In the Q1 2025 earnings call, Fresenius reported a strong start to the fiscal year, reaffirming its full-year guidance. Key metrics highlighted include a 7% organic top-line growth and 4% EBIT growth at constant currency, alongside a significant 12% increase in EPS due to improved capital deployment and portfolio optimization. Kabi achieved a notable EBIT margin of 16.8%, propelled by its growth vectors, particularly in biopharma, which is nearing its structural EBIT margin range of 16% to 18%. Helios also showed robust performance, with Helios Spain achieving a 13.1% EBIT margin, while Helios Germany continues to focus on process efficiencies. The company has tightened its leverage target to a corridor of 2.5 to 3.0 net debt over EBITDA, ending the first quarter within this range. Additionally, Fresenius highlighted the successful sale of Fresenius Medical Care shares, which contributed to its strategic flexibility and balance sheet strength.

Strong Start to 2025

Fresenius reported a strong start to 2025 with excellent momentum across its businesses and reconfirmed its full-year guidance.

Double-Digit EPS Growth

The company achieved a double-digit EPS growth, reflecting efforts in turning around the company with a 12% increase in core EPS performance in the first quarter.

Kabi's Strong Performance

Kabi delivered strong top line growth driven by biopharma, with an EBIT margin increase to 16.8% and organic revenue growth of 6%.

Helios' Encouraging Start

Helios had an encouraging start to the year with organic revenue growth of 8% and Helios Spain achieving a 13.1% EBIT margin.

Deleveraging and Balance Sheet Strength

The company reduced its leverage to 3x net debt to EBITDA and aims to further strengthen the balance sheet with proceeds from the divestment of Fresenius Medical Care.

Biopharma Momentum

Biopharma showed significant momentum with 40% organic top line growth and profitability improvements.

Fresenius SE & Co (FSNUY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FSNUY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.22 / -	0.185	―	―	―
Aug 06, 2025	2025 (Q2)	0.22 / 0.25	0.218	15.14% (+0.03)
May 07, 2025	2025 (Q1)	0.21 / 0.25	0.204	21.08% (+0.04)
Feb 26, 2025	2024 (Q4)	0.18 / 0.20	0.189	4.23% (<+0.01)
Nov 06, 2024	2024 (Q3)	0.18 / 0.18	0.162	14.20% (+0.02)
Jul 31, 2024	2024 (Q2)	0.19 / 0.22	0.185	17.84% (+0.03)
May 08, 2024	2024 (Q1)	0.19 / 0.20	0.189	7.94% (+0.01)
Feb 21, 2024	2023 (Q4)	0.20 / 0.19	0.211	-10.43% (-0.02)
Nov 02, 2023	2023 (Q3)	0.16 / 0.16	0.17	-4.71% (>-0.01)
Aug 02, 2023	2023 (Q2)	0.17 / 0.18	0.203	-8.87% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FSNUY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$11.98	$12.10	+1.00%
May 07, 2025	$11.90	$12.09	+1.60%
Feb 26, 2025	$9.45	$10.07	+6.56%
Nov 06, 2024	$9.08	$9.18	+1.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fresenius SE & Co (FSNUY) report earnings?

Fresenius SE & Co (FSNUY) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Fresenius SE & Co (FSNUY) earnings time?

Fresenius SE & Co (FSNUY) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is FSNUY EPS forecast?

FSNUY EPS forecast for the fiscal quarter 2025 (Q3) is 0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing